A newly published study in the journal Cancer Research (appearing in print on February 1) signals a potential treatment breakthrough for patients with triple negative breast cancer—a form of the disease that disproportionately ...
Jan 29, 2020
0
15
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows.
Dec 3, 2019
0
2
In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine (UMSOM) have identified a new pathway that leads to the destruction of cancer cells. The new finding, ...
Oct 15, 2019
0
84
A new study shows that tumor cells depleted of ARID1A—a protein that acts as a cancer suppressor—become highly sensitive to anticancer poly ADP ribose polymerase (PARP) inhibitor drugs after radiation treatment. The research, ...
Aug 19, 2019
0
4
July 24, 2019—A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating ...
Jul 24, 2019
0
3
New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy.
Jul 8, 2019
0
0
Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives in a meaningful way. However, a new research study shows ...
Jul 3, 2019
0
4
Researchers from the University of Montreal Hospital Research Centre (CRCHUM) have developed a two-step combination therapy to destroy cancer cells. In a study published in the journal Nature Communications, they show the ...
Jun 11, 2019
0
234
Medications known as PARP inhibitors have emerged as a promising therapy for several forms of cancer fueled by a defect in the cells' DNA repair machinery. Yet many people with cancers caused by the defect, known as HR deficiency, ...
Apr 15, 2019
0
155
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, ...
Apr 2, 2019
0
1
